Molecular characterization of anastrozole resistance in breast cancer: pivotal role of the Akt/mTOR pathway in the emergence of de novo or acquired resistance and importance of combining the allosteric Akt inhibitor MK-2206 with an aromatase inhibit
about
The dark side of ZNF217, a key regulator of tumorigenesis with powerful biomarker valueManagement of patients with hormone receptor-positive breast cancer with visceral disease: challenges and treatment optionsIn-vitro and in-vivo combined effect of ARQ 092, an AKT inhibitor, with ARQ 087, a FGFR inhibitor.Inhibition of Autophagy Promotes Salinomycin-Induced Apoptosis via Reactive Oxygen Species-Mediated PI3K/AKT/mTOR and ERK/p38 MAPK-Dependent Signaling in Human Prostate Cancer Cells.Hormone Resistance in Two MCF-7 Breast Cancer Cell Lines is Associated with Reduced mTOR Signaling, Decreased Glycolysis, and Increased Sensitivity to Cytotoxic Drugs.Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways.AR collaborates with ERα in aromatase inhibitor-resistant breast cancer.MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancerEndocrine resistance in breast cancer.Targeting the androgen receptor in breast cancer.Hormone receptor positive, HER2 negative metastatic breast cancer: Future treatment landscape.A functional interplay between ZNF217 and estrogen receptor alpha exists in luminal breast cancers.In vitro and in vivo anti-cancer activity of formononetin on human cervical cancer cell line HeLa.The Therapeutic Potential of PI3K/Akt/mTOR Inhibitors in Breast Cancer: Rational and Progress.Overcoming Resistance to Endocrine Therapy in Breast Cancer: New Approaches to a Nagging Problem.TransCONFIRM: Identification of a Genetic Signature of Response to Fulvestrant in Advanced Hormone Receptor-Positive Breast Cancer.Contribution of nucleophosmin overexpression to multidrug resistance in breast carcinoma.Translational studies within the TAMRAD randomized GINECO trial: evidence for mTORC1 activation marker as a predictive factor for everolimus efficacy in advanced breast cancer.Signaling pathways and steroid receptors modulating estrogen receptor α function in breast cancer
P2860
Q26782620-FDD1C9A6-18B2-4E40-8FEE-4A1D5B140C4AQ26995549-54051784-8615-43D5-8053-86107A965E14Q33601377-D44155BB-C6D7-479F-B95D-FA4D1B0129BFQ33755426-8B9C47A4-89EF-4848-BE83-110766BCAEF1Q34125846-17448586-BAAA-4437-B082-9C7013690195Q34147910-E341FA6A-7E74-46F7-A3D0-6646C76B2637Q35112392-17D642AC-E98A-4C9A-A589-B1F4C8B5C699Q35128098-9973C601-134E-46B2-8C16-F80C8AA3E807Q38163573-47401590-2DB6-4529-8A86-BB480AEE2BF1Q38349376-62E882B2-76D7-4671-B519-ACD0707B10C0Q38784119-FCF36252-D9C2-4090-A469-F1388C92BE83Q38980243-EC7BF44C-DFAB-4AE7-9272-C37BE222DB56Q39056096-317A3E90-D8FD-4D27-BDE1-EAAC981AD059Q39312902-7F74D73E-2EAA-485E-BC92-D29FBD1A871CQ42755954-00645DD0-5A46-44C3-82F3-1DCFE6FCD0E4Q49537165-E6FC2844-CCAD-4E55-91F7-15CDB4D53BCDQ53738419-F33A3C6B-9285-4EDA-8C0A-ECD0EC332BC0Q54312158-31D40BB0-9E2E-41EF-92A7-2B1E30C21611Q57106904-E15F3340-E4D7-4289-8342-8F47F35CEB1D
P2860
Molecular characterization of anastrozole resistance in breast cancer: pivotal role of the Akt/mTOR pathway in the emergence of de novo or acquired resistance and importance of combining the allosteric Akt inhibitor MK-2206 with an aromatase inhibit
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Molecular characterization of ...... 2206 with an aromatase inhibit
@en
Molecular characterization of ...... 2206 with an aromatase inhibit
@nl
type
label
Molecular characterization of ...... 2206 with an aromatase inhibit
@en
Molecular characterization of ...... 2206 with an aromatase inhibit
@nl
prefLabel
Molecular characterization of ...... 2206 with an aromatase inhibit
@en
Molecular characterization of ...... 2206 with an aromatase inhibit
@nl
P2093
P2860
P356
P1476
Molecular characterization of ...... 2206 with an aromatase inhibit
@en
P2093
Evelyne Grisard
Isabelle Treilleux
Julie A Vendrell
Laura Corbo
Marie Villedieu
Pascale A Cohen
Paul Vilquin
Pierre-Etienne Heudel
Sabrina Ben Larbi
Sandra E Ghayad
P2860
P304
P356
10.1002/IJC.28182
P577
2013-05-02T00:00:00Z